Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Effects of arsenic compounds on apoptosis, cell cycle
and DNA methylation on myelodysplastic syndromes cells and leukemia cells

  • In: Poster Presentation
  • At: Stockholm (Sweden) (2017)
  • Type: Poster
  • Poster code: P-A-048-Tuesday
  • By: TANAKA, Sachiko (Tokyo University Of Phramacy And Life Sciences, Hachioji, Japan)
  • Co-author(s): Sachiko Tanaka: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Fang Su : National Therapeutic Center of Hematology of Traditional Chinese Medicine, XiYuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
    Qing-Bing Zhou: National Therapeutic Center of Hematology of Traditional Chinese Medicine, XiYuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
    Hu Xiaomei: National Therapeutic Center of Hematology of Traditional Chinese Medicine, XiYuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
    Kenji Onda: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Taku Furukawa: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Kentaro Sugiyama: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Anna Kiyomi: Department of Drug Safety Management, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Hironori Takeuchi: Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Sakae Unezaki: Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Haruki Yamada: Department of Kampo Medicines, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Takao Akashi: Department of Pharmaceutics, Tokyo Medical University, Tokyo, Japan
    Toshihiko Hirano: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
  • Abstract:

    Backgrounds

    Arsenic has been used for the treatment of malignant hematologic diseases including Myelodysplastic syndromes (MDS), which are a group of clonal disorders of haematopoietic stem cells characterised by ineffective haematopoiesis and a tendency to evolve into acute myeloid leukaemia (AML). Arsenic trioxide (As2O3) has been confirmed to be ..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses